Program
PRAME mRNA Vaccine mRNA-4203
Its studies are mostly in Melanoma, led by Immatics US.
Furthest: phase 1, since Apr 19, 20251 company-led study, 1 open or runningNext primary completion: Aug 2029 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Immatics US | 11 open or running | phase 1since Apr 19, 2025 | Apr 19, 2025 | Aug 2029phase 1 · NCT06946225 |
Also a collaborator on its studies: Moderna.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 19, 2025First study: phase 1 study in MelanomaFirst studyNCT06946225 · 15 planned · United States
Ahead
- Aug 2029Primary completion: phase 1 study in MelanomaNCT06946225
TargetBeta
PRAME →read by rule
“A cancer vaccine consisting of a lipid nanoparticle (LNP) encapsulating messenger RNA (mRNA) encoding for the tumor-associated antigen (TAA) preferentially expressed antigen in melanoma (PRAME), ”NCIt, by rule
Other programs on PRAME
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| anzutresgene autoleucelrule | Immatics US | phase 3 | 3 |
| Autologous Anti-PRAME TCR-expressing T-cells OPB-201rule | outpace-bio-inc | phase 1 | 1 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06946225Melanoma · United States | 1 | Recruiting | Aug 2029 | 15 |
How it is read
Names in the registry
- “mRNA-4203”, 1 entry
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.